teva pharmaceutical-sp adr
Transactions by TEVA PHARMACEUTICAL-SP ADR (TEVA) in the last 6 months
ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) acquired 22 generic drug products from Teva Pharmaceutical Industries Limited (NYSE:TEVA) for $25 million on July 10, 2015. ANI Pharmaceuticals will pay $25 million in cash and a percentage of future gross profits from product sales. The acquisition is being funded through cash on hand.
Microchips Biotech, Inc. announced that it will receive $18,648,546 in funding on June 17, 2015. The company will issue common stock in the transaction. The transaction will include participation from five investors. The company will issue securities pursuant to exemption provided under Regulation D.
On June 18, 2015, the company amended the terms of the transaction. The company announced that it has entered in to an agreement to receive $35,000,000 in an equity funding ...
American Well Corporation announced that it will receive tens of millions of dollars funding from new investor, Teva Pharmaceutical Industries Limited on June 2, 2015.
Soros Fund Management LLC sold all of its 0.6% stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the first quarter of 2015. Soros Fund Management sold all the 4.9 million shares of Teva held by it.
ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) acquired New Drug Application for Testosterone Gel from Teva Pharmaceutical Industries Limited (NYSE:TEVA) for $5 million on May 13, 2015. Upon commercialization, ANI will pay Teva up to $5 million at a rate of 5% of the consideration received by ANI as a result of commercial sale of the product.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) made a proposal to acquire Mylan N.V. (NasdaqGS:MYL) for $31 billion on April 21, 2015. Teva offered $82 a share in cash and stock for Mylan. The consideration would comprise of approximately 50% cash and 50% stock. The proposal was unanimously approved by the Board of Directors of Teva. This proposal is subject to customary conditions. The transaction would not be subject to a financing condition or require a Teva stockholder ...
Paulson & Co. Inc.
The Goldman Sachs Group, Inc.
Spinath & Wakkie
Teva Pharmaceutical Industries Limited (NYSE:TEVA) entered into a definitive agreement to acquire Auspex Pharmaceuticals, Inc. (NasdaqGM:ASPX) from a group of shareholders for $3.2 billion in cash on March 29, 2015. The group of shareholders includes Thomas, McNerney & Partners, Panorama Capital, CMEA Capital, Foresite Capital Management, L.L.C. and other shareholders. Under the terms of the deal, Teva will commence a tender offer for all of the outstanding shares of ...
Deerfield Capital, L.P.
Deerfield Management Company, L.P.
Deerfield Private Design Fund II, L.P.
Deerfield Private Design International II, Ltd.
Deerfield Special Situations Fund, LP
Deerfield Special Situations International Master Fund, L.P.
Foresite Capital Management, L.L.C.
Oxford Finance LLC
Panorama Capital I, L.P.
Presidio Partners 2007
Thomas, McNerney & Partners
Thomas, McNerney & Partners II, L.P.
G & W Laboratories, Inc. signed an agreement to acquire Sellersville, Pennsylvania facility from Teva Pharmaceutical Industries Limited (NYSE:TEVA) on March 2, 2015. The transaction includes the grant to G & W of exclusive rights to sell up to two additional Teva products in the U.S. under G & W's label, which Teva will continue to manufacture at its Zagreb, Croatia facility. G & W Laboratories will offer employment to all the employees located in acquire Sellersville. ...
|Abbott Laboratories||$50.69 USD||-0.08|
|AbbVie Inc||$70.01 USD||-0.15|
|AstraZeneca PLC||4,320 GBp||+0.50|
|Eli Lilly & Co||$84.51 USD||-0.03|
|Medtronic PLC||$78.39 USD||+0.11|
|View Industry Companies|